Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00072930
Status:
COMPLETED
Last Update Posted:
2008-01-15
First Post:
2003-11-12
Brief Title:
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
Phase II Randomized Open-Label Two-Arm Multicenter Study of MEDI-522 a HuMA Directed Against the Human Alpha V Beta 3 Integrin in Combination With Docetaxel Prednisone and Zoledronic Acid in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objectives of this study are
1 To explore the antitumor activity of MEDI-522 in combination with docetaxel prednisone and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer AIPC and
2 To summarize the safety of MEDI-522 in combination with docetaxel prednisone and zoledronic acid in this patient population
1 To explore the antitumor activity of MEDI-522 in combination with docetaxel prednisone and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer AIPC and
2 To summarize the safety of MEDI-522 in combination with docetaxel prednisone and zoledronic acid in this patient population
Detailed Description:
This is a Phase II randomized open-label two-arm multicenter study of MEDI-522 in combination with docetaxel prednisone and zoledronic acid in patients with metastatic AIPC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None